Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia

Leuk Res. 2012 Jul;36(7):817-25. doi: 10.1016/j.leukres.2012.01.021. Epub 2012 Feb 23.


Ensuring adherence to therapy is a challenge in chronic diseases, particularly in cancers such as chronic myeloid leukemia (CML), where there has been increased availability and use of oral formulations. A conceptual model of adherence was developed based on findings from a comprehensive literature review, to inform strategies for improving adherence to oral CML therapies. A complex interplay of factors (including clinical, psychological and behavioural) influence adherence to such therapies. Healthcare professionals have a key role in promoting and facilitating adherence and future strategies should place greater emphasis on understanding patient-level experiences in order to create personalized solutions.

Publication types

  • Evaluation Study
  • Review

MeSH terms

  • Administration, Oral
  • Antineoplastic Agents / administration & dosage
  • Clinical Trials as Topic / statistics & numerical data
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / epidemiology
  • Medication Adherence / statistics & numerical data*
  • Models, Biological
  • Patient Satisfaction / statistics & numerical data
  • Protein Kinase Inhibitors / administration & dosage*


  • Antineoplastic Agents
  • Protein Kinase Inhibitors